OncoMatch/Clinical Trials/Endometrial / Uterine Cancer
Endometrial / Uterine Cancer Clinical Trials
OncoMatch filters Endometrial / Uterine Cancer trials by the molecular markers that determine eligibility — MMR, POLE, PTEN, CD274, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Endometrial / Uterine Cancer trials
These are the molecular markers most commonly required or evaluated in Endometrial / Uterine Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Endometrial / Uterine Cancer trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc.
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
BioNTech SE
How OncoMatch finds Endometrial / Uterine Cancer trials for you
AI reads the protocol
Every Endometrial / Uterine Cancer trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Endometrial / Uterine Cancer and mark your biomarker results — MMR, POLE, PTEN — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.